Coronary artery bypass grafting versus drug‐eluting stents in patients with severe coronary artery disease and diabetes mellitus: Systematic review and meta‐analysis 冠状动脉旁路移植术与药物洗脱支架治疗严重冠心病合并糖尿病的患者：系统评估和meta分析

Abstract

Background: A comprehensive meta-analysis was performed to evaluate the comparative benefits of coronary artery bypass grafting (CABG) versus drugeluting stents (DES) in patients with diabetes mellitus and severe coronary artery disease (CAD). Methods: A comprehensive literature search of PubMed, Embase, and ScienceDirect was undertaken. References cited with the papers were also checked to identify relevant articles. Results: In all, four randomized controlled trials, two prospective registries, and 11 retrospective studies were identified for review. Pooled analysis demonstrated that DES was associated with lower all-cause mortality at Day 30. However, there was no significant difference between CABG and DES in mortality at 12 months and at maximum follow-up. Furthermore, DES was associated with lower overall and major adverse cardiac and cerebrovascular events (MACCE)-free survival, as well as a higher incidence of myocardial infarction and repeat revascularization. In contrast, CABG was associated with an increased risk of stroke. Conclusions: For patients with diabetes mellitus and severe CAD, CABG is superior to DES in that it significantly improves overall and MACCE-free survival and reduces the incidence of myocardial infarction and repeat revascularization in the long term, although it is associated with greater perioperative risk and a higher incidence of stroke. Therefore, CABG should remain the gold standard for these patients.

Coronary artery bypass vs percutaneous coronary intervention in under 50s

“…In a comprehensive meta‐analysis evaluating the comparative benefits of CABG vs drug‐eluting stents (DES) in patients with diabetes mellitus and severe CAD, the authors conclude that CABG is superior to DES in that it significantly improves overall and MACCE‐free survival and reduces the incidence of MI and repeat revascularization in the long term, although it is associated with greater perioperative risk and a higher incidence of stroke.…”

Myocardial revascularization in patients with coronary heart disease and type 2 diabetes

“…Данные о влиянии реваскуляризации миокарда на пациентов с СД были получены параллельно с разви-тием технологий ЧКВ, КШ и фармакотерапии, и потому сложно проводить прямые сопоставления, но в настоя-щее время накоплены убедительные доказательства того, что отдаленные результаты КШ при многососудистом поражении коронарных артерий и диабете превосходят таковые при ЧКВ, даже при использовании стентов с ле-карственным покрытием [16,18,[21][22][23][24][25][26].…”

Safety and efficacy of zotarolimus‐eluting stents in the treatment of diabetic coronary lesions in Chinese patients: The RESOLUTE‐DIABETES CHINA Study

“…It has been well established that outcomes following coronary revascularization are consistently poorer among patients with diabetes than for patients without diabetes . Although percutaneous coronary intervention (PCI) has not been shown to be fully comparable to coronary artery bypass grafting (CABG) in the diabetic population for repeat revascularizations, the use of drug‐eluting stents (DES) has markedly reduced mortality and the rate of myocardial infarction (MI) in all patients compared with the use of bare‐metal stents (BMS), as well as narrowing the gap between PCI and CABG for diabetic patients …”